Concomitant vitiligo and psoriasis in a patient treated with interferon alfa-2a for chronic hepatitis B infection
PEDIATRIC DERMATOLOGY, cilt.21, sa.5, ss.577-579, 2004 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 21 Sayı: 5
- Basım Tarihi: 2004
- Doi Numarası: 10.1111/j.0736-8046.2004.21512.x
- Dergi Adı: PEDIATRIC DERMATOLOGY
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.577-579
- Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Hayır
Özet
Well-known cutaneous side effects of interferon (IFN)-alfa therapy include dry skin, pruritus, hair loss, and psoriasis. Presumably because of its potent immunomodulatory activity, the use of IFN-alfa has also led to the development of autoimmune diseases in susceptible individuals. Vitiligo, an autoimmune cutaneous disease, has been reported to occur during IFN-alfa therapy. We report a 10-year-old girl with chronic hepatitis B infection in whom IFN-alfa treatment induced de novo development of vitiligo and psoriasis. Neither skin condition improved after withdrawal of interferon treatment. Concomitant occurrence of vitiligo and psoriasis due to IFN-alfa has not been reported previously.